| The role of oxidative stress in Parkinson's disease V Dias, E Junn, MM Mouradian Journal of Parkinson's disease 3 (4), 461-491, 2013 | 1797 | 2013 |
| Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease AW Dunah, H Jeong, A Griffin, YM Kim, DG Standaert, SM Hersch, ... Science 296 (5576), 2238-2243, 2002 | 850 | 2002 |
| Dopamine receptor regulating factor, DRRF: a zinc finger transcription factor CK Hwang, UM D'Souza, AJ Eisch, S Yajima, CH Lammers, Y Yang, ... Proceedings of the National Academy of Sciences 98 (13), 7558-7563, 2001 | 812 | 2001 |
| Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease MP HEYES, K Saito, JS Crowley, LE Davis, MA Demitrack, M Der, ... Brain 115 (5), 1249-1273, 1992 | 781 | 1992 |
| Repression of α-synuclein expression and toxicity by microRNA-7 E Junn, KW Lee, BS Jeong, TW Chan, JY Im, MM Mouradian Proceedings of the National Academy of Sciences 106 (31), 13052-13057, 2009 | 730 | 2009 |
| Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease LV Metman, P Del Dotto, P Van Den Munckhof, J Fang, MM Mouradian, ... Neurology 50 (5), 1323-1326, 1998 | 683 | 1998 |
| Quinolinic acid in cerebrospinal fluid and serum in HIV‐1 infection: relationship to clinical and neurological status MP Heyes, BJ Brew, A Martin, RW Price, AM Salazar, JJ Sidtis, JA Yergey, ... Annals of Neurology: Official Journal of the American Neurological …, 1991 | 678 | 1991 |
| Degradation of α-synuclein by proteasome MC Bennett, JF Bishop, Y Leng, PB Chock, TN Chase, MM Mouradian Journal of Biological Chemistry 274 (48), 33855-33858, 1999 | 569 | 1999 |
| Aggresomes formed by α-synuclein and synphilin-1 are cytoprotective M Tanaka, YM Kim, G Lee, E Junn, T Iwatsubo, MM Mouradian Journal of Biological Chemistry 279 (6), 4625-4631, 2004 | 524 | 2004 |
| Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death E Junn, H Taniguchi, BS Jeong, X Zhao, H Ichijo, MM Mouradian Proceedings of the National Academy of Sciences 102 (27), 9691-9696, 2005 | 424 | 2005 |
| Adenosine A2A receptor antagonist treatment of Parkinson’s disease W Bara-Jimenez, A Sherzai, T Dimitrova, A Favit, F Bibbiani, M Gillespie, ... Neurology 61 (3), 293-296, 2003 | 385 | 2003 |
| Recent advances in the genetics and pathogenesis of Parkinson disease MM Mouradian Neurology 58 (2), 179-185, 2002 | 379 | 2002 |
| Mitochondrial localization of DJ‐1 leads to enhanced neuroprotection E Junn, WH Jang, X Zhao, BS Jeong, MM Mouradian Journal of neuroscience research 87 (1), 123-129, 2009 | 370 | 2009 |
| Human α-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine E Junn, MM Mouradian Neuroscience letters 320 (3), 146-150, 2002 | 336 | 2002 |
| Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II MM Mouradian, JL Junecos, G Fabbrini, J Schlegel, JJ Bartko, TN Chase Annals of Neurology: Official Journal of the American Neurological …, 1988 | 331 | 1988 |
| Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I G Fabbnni, MM Mouradian, JL Junecos, J Schlegel, E Mohr, TN Chase Annals of Neurology: Official Journal of the American Neurological …, 1988 | 325 | 1988 |
| Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies E Junn, RD Ronchetti, MM Quezado, SY Kim, MM Mouradian Proceedings of the National Academy of Sciences 100 (4), 2047-2052, 2003 | 302 | 2003 |
| Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease MM Mouradian, IJE Heuser, F Baronti, TN Chase Annals of Neurology: Official Journal of the American Neurological …, 1990 | 295 | 1990 |
| MicroRNAs in neurodegenerative diseases and their therapeutic potential E Junn, MM Mouradian Pharmacology & therapeutics 133 (2), 142-150, 2012 | 264 | 2012 |
| Apoptotic signaling in dopamine‐induced cell death: the role of oxidative stress, p38 mitogen‐activated protein kinase, cytochrome c and caspases E Junn, MM Mouradian Journal of Neurochemistry 78 (2), 374-383, 2001 | 260 | 2001 |
